Research Topics
| W SievertSummaryAffiliation: Monash University Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia majorWilliam Sievert
Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia
Am J Gastroenterol 97:982-7. 2002..HIC may be a factor in liver cell injury, but it does not reliably predict a response to interferon therapy...- Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon aloneW Sievert
Department of Medicine, Monash Medical Centre, Monash University, Melbourne, Clayton, Vic, Australia
Aliment Pharmacol Ther 17:1197-204. 2003..High-dose induction interferon may enhance early viral clearance, whilst ribavirin reduces relapse; in combination, they may improve sustained virological response rates... - Management issues in chronic viral hepatitis: hepatitis CWilliam Sievert
Monash University Department of Medicine, Monash Medical Centre, 246 Clayton Road, Melbourne 3168, Australia
J Gastroenterol Hepatol 17:415-22. 2002..Current data strongly support the concept that SVR in HCV infection (or treatment-induced latency) provides a cure in terms of its beneficial effects on quality of life and sustained amelioration of liver injury... 
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trialStuart K Roberts
The Alfred, Melbourne, Australia
Hepatology 50:1045-55. 2009..The high SVR rates in patients with minimal fibrosis highlight the benefit of early treatment in patients with hepatitis C virus genotype 1...- Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcomeAnouk T Dev
Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia
Hepatology 36:1259-65. 2002..This study also supports the concept that race and ethnicity are important determinants of treatment outcome in HCV infected patients... - Transplantation of human amnion epithelial cells reduces hepatic fibrosis in immunocompetent CCl₄-treated miceUrsula Manuelpillai
Centre for Reproduction and Development, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia
Cell Transplant 19:1157-68. 2010..hAEC transplantation into immunocompetent mice leads to cell engraftment, reduced hepatocyte apoptosis, and decreased hepatic inflammation and fibrosis... - A survey of Australian general practice management of hepatitis C-infected patients from non-English-speaking backgroundsAnouk Dev
Monash University Department of Medicine, Monash Medical Center, Melbourne, Victoria, Australia
J Gastroenterol Hepatol 17:295-300. 2002..General practitioners, who are often the first health professionals consulted, need to be aware of risk factors and complications associated with hepatitis C in this group... - Antiviral therapy for chronic hepatitis CWilliam Sievert
Departments of Medicine and Gastroenterology, Monash University, Monash Medical Centre, Victoria
Aust Fam Physician 32:826-32. 2003 - Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infectionS Pianko
Monash University, Department of Medicine and Gastroenterology Unit, Monash Medical Centre, Melbourne, Australia
J Viral Hepat 8:406-13. 2001..The correlation between Fas expression and TUNEL supports the hypothesis that the Fas-Fas ligand interaction is the major mechanism for HCV-induced hepatocyte apoptosis... - Ethnic and cultural determinants influence risk assessment for hepatitis C acquisitionAnouk Dev
Monash University Department of Medicine and Department of Gastroenterology, Monash Medical Center, Melbourne, Victoria, Australia
J Gastroenterol Hepatol 19:792-8. 2004..Accurate risk factor assessment is essential for education targeted at risk reduction in culturally diverse populations... - Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitisS Patella
Department of Medicine, Centre for Inflammatory Diseases, Monash Medical Centre, Monash University, Clayton, Victoria, Australia
J Hepatol 34:576-83. 2001..Dysregulation of the activin/follistatin axis may be linked to hepatitis B replication but does not correlate with hepatocyte apoptosis... - Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated ratJohn S Lubel
Department of Medicine, The University of Melbourne, Austin Health and Northern Health, Vic, Australia
Clin Sci (Lond) 117:375-86. 2009..In conclusion, Ang-(1-7) is up-regulated in human liver disease and has antifibrotic actions in a rat model of cirrhosis. The ACE2/Ang-(1-7)/mas receptor axis represents a potential target for antifibrotic therapy in humans... - Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infectionMark Danta
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW
Med J Aust 177:240-5. 2002..There was no association in either analysis with sex or source of HCV infection. CONCLUSION: These factors may assist in targeting patients for both liver biopsy-based investigation and therapeutic intervention... - Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trialHenry L Y Chan
The Chinese University of Hong Kong, Shatin, Hong Kong, China
Ann Intern Med 147:745-54. 2007..The efficacy of nucleoside and nucleotide analogues for hepatitis B has been linked to the magnitude and durability of hepatitis B virus (HBV) suppression... - Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BPatrick Marcellin
Hopital Beaujon, Paris, France
Hepatology 48:750-8. 2008..There were no serious adverse events related to ADV. CONCLUSION: Treatment with ADV beyond 48 weeks was well tolerated and produced long-term virological, biochemical, serological, and histological improvement... - Serum alanine aminotransferase levels and the detection of hepatitis C virus (HCV) in chronic HCV infectionsHeath A Kelly
Med J Aust 176:139. 2002 - Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BPatrick Marcellin
Service d Hepatologie, INSERM Unité 481, and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
N Engl J Med 348:808-16. 2003..In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains...